Suppr超能文献

门静脉高压症血管病变的研究进展

Research progress of vasculopathy in portal hypertension.

作者信息

Li Tao, Yang Zhen

机构信息

Department of General Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.

出版信息

World J Gastroenterol. 2005 Oct 21;11(39):6079-84. doi: 10.3748/wjg.v11.i39.6079.

Abstract

Portal hypertension, one of the vascular diseases, not only has lesions in liver, but also changes in vascular structures and functions of extrahepatic portal system, systemic system and pulmonary circulation. The pathological changes of vasculopathy in portal hypertension include remodeling of arterialized visceral veins, intimal injury of visceral veins and destruction of contractile structure in visceral arterial wall. The mechanisms of vasculopathy in portal hypertension may be attributed to the changes of hemodynamics in portal system, immune response, gene modulation, vasoactive substances, and intrahepatic blood flow resistance. Portal hypertension can cause visceral hyperdynamic circulation, and the development and progression of visceral vasculopathy, while visceral vasculopathy can promote the development and progression of portal hypertension and visceral hyperdynamic circulation in turn. The aforementioned three factors interact in the pathogenesis of hepatic cirrhosis-induced portal hypertension and are involved in hemorrhage due to varicose vein rupture.

摘要

门静脉高压是一种血管疾病,不仅肝脏存在病变,肝外门静脉系统、全身系统及肺循环的血管结构和功能也会发生改变。门静脉高压时血管病变的病理变化包括内脏静脉动脉化重塑、内脏静脉内膜损伤以及内脏动脉壁收缩结构破坏。门静脉高压时血管病变的机制可能归因于门静脉系统血流动力学改变、免疫反应、基因调控、血管活性物质及肝内血流阻力。门静脉高压可导致内脏高动力循环以及内脏血管病变的发生和进展,而内脏血管病变又可反过来促进门静脉高压和内脏高动力循环的发展和进展。上述三个因素在肝硬化所致门静脉高压的发病机制中相互作用,并参与静脉曲张破裂出血。

相似文献

1
Research progress of vasculopathy in portal hypertension.
World J Gastroenterol. 2005 Oct 21;11(39):6079-84. doi: 10.3748/wjg.v11.i39.6079.
2
Splenic vasculopathy in portal hypertension patients.
World J Gastroenterol. 2006 May 7;12(17):2737-41. doi: 10.3748/wjg.v12.i17.2737.
3
Pathophysiology and treatment of variceal hemorrhage.
Mayo Clin Proc. 1996 Oct;71(10):973-83. doi: 10.1016/S0025-6196(11)63772-5.
4
Pathophysiology of portal hypertension.
J Physiol Pharmacol. 2008 Aug;59 Suppl 2:231-8.
5
Liver microvascular architecture: an insight into the pathophysiology of portal hypertension.
Semin Liver Dis. 1999;19(4):359-82. doi: 10.1055/s-2007-1007126.
6
Portal venous system measurements in portal hypertension.
Radiology. 1984 Apr;151(1):27-30. doi: 10.1148/radiology.151.1.6701328.
8
Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives.
World J Gastroenterol. 2018 Sep 7;24(33):3738-3748. doi: 10.3748/wjg.v24.i33.3738.
9
Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.
J Hepatol. 2014 Oct;61(4):912-24. doi: 10.1016/j.jhep.2014.05.047. Epub 2014 Jun 6.
10
Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
Am J Physiol Gastrointest Liver Physiol. 2009 Oct;297(4):G792-9. doi: 10.1152/ajpgi.00229.2009. Epub 2009 Jul 23.

引用本文的文献

1
The natural history of portal venous system aneurysms.
J Vasc Surg Venous Lymphat Disord. 2025 May;13(3):102163. doi: 10.1016/j.jvsv.2024.102163. Epub 2024 Dec 27.
4
Monitoring the Progression of Chronic Liver Damage in Rats Using [F]PBR06.
Mol Imaging Biol. 2019 Aug;21(4):669-675. doi: 10.1007/s11307-018-1282-z.
5
Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis.
World J Gastroenterol. 2009 Sep 28;15(36):4529-37. doi: 10.3748/wjg.15.4529.
6
Experimental obstructive cholestasis: the wound-like inflammatory liver response.
Fibrogenesis Tissue Repair. 2008 Nov 3;1(1):6. doi: 10.1186/1755-1536-1-6.

本文引用的文献

1
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.
Science. 2002 Dec 6;298(5600):1911-2. doi: 10.1126/science.1072682.
2
Growth factors enhance interleukin-1 beta-induced persistent activation of nuclear factor-kappa B in rat vascular smooth muscle cells.
Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1811-6. doi: 10.1161/01.atv.0000037679.60584.3f.
3
Mitogenic activity of oxidized lipoprotein (a) on human vascular smooth muscle cells.
Hypertension. 2002 Sep;40(3):310-4. doi: 10.1161/01.hyp.0000029974.50905.b4.
4
Hypoxia activates beta(1)-integrin via ERK 1/2 and p38 MAP kinase in human vascular smooth muscle cells.
Biochem Biophys Res Commun. 2002 Aug 30;296(4):890-6. doi: 10.1016/s0006-291x(02)02033-8.
7
Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin.
Cell Signal. 2002 Aug;14(8):649-54. doi: 10.1016/s0898-6568(02)00007-4.
10
[Portal hypertensive vasculopathy of splenic artery].
Zhonghua Wai Ke Za Zhi. 1999 Jul;37(7):412-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验